Antiglaucoma Medications
Mahahalagang Punto
- Ang pamamahala ng chronic primary open-angle glaucoma (POAG) ay nakasentro sa tuloy-tuloy na pagbaba ng intraocular pressure (IOP) upang mapabagal ang optic-nerve damage.
- Ang acute angle-closure glaucoma ay emergency: ang matinding sakit ng mata/ulo na may mabilis na pagtaas ng IOP ay maaaring magdulot ng permanenteng pagkawala ng paningin sa loob ng 24-48 oras.
- Kabilang sa first-line topical classes para sa POAG ang beta blockers, alpha-2 adrenergic agonists, at prostaglandin analogues; karaniwang adjuncts ang carbonic anhydrase inhibitors.
- Ang rho kinase inhibitors ay karagdagang topical options na nagpapataas ng trabecular outflow.
- Madalas na kailangan ang combination therapy dahil iba-iba ang mekanismo ng pagbaba ng IOP ng bawat drug class.
Clinical Use Framework
Pinabababa ng antiglaucoma drugs ang IOP sa pamamagitan ng pagbawas ng aqueous-humor production o pagtaas ng aqueous outflow. Pangmatagalan ang POAG treatment at kadalasang asymptomatic, kaya pangunahing nursing priorities ang adherence at follow-up pressure checks.
Sa acute angle-closure pathways, mabilis na ginagamit ang mga gamot upang pababain ang IOP at patatagin ang sintomas bago ang definitive procedural/surgical management.
Drug Classes and Typical Dosing Patterns
| Class | Representative Agents | Typical Adult Ophthalmic Pattern | Core Action |
|---|---|---|---|
| Beta-adrenergic blockers | Timolol, betaxolol, carteolol | Usually 1 drop once or twice daily depending on product | Decrease aqueous production |
| Prostaglandin analogues | Latanoprost, bimatoprost, travoprost | 1 drop in affected eye(s) once nightly | Increase aqueous outflow (uveoscleral/trabecular pathways) |
| Alpha-2 adrenergic agonists | Brimonidine; brimonidine/timolol combination | Often 1 drop every 8 hours (product-dependent) | Decrease aqueous production and increase outflow |
| Carbonic anhydrase inhibitors | Dorzolamide, brinzolamide | Usually 1 drop 2-3 times daily (regimen-dependent) | Decrease aqueous production |
| Rho kinase inhibitors | Netarsudil | 1 drop in affected eye(s) each evening | Increase trabecular outflow |
Adverse Effects and Contraindications
- Beta blockers: bradycardia, hypotension, heart block, bronchospasm; iwasan sa severe asthma/COPD, sinus bradycardia, advanced AV block, severe heart failure, cardiogenic shock.
- Prostaglandin analogues: ocular hyperemia, stinging, blurred vision, eyelash growth at periocular/iris pigmentation changes; iwasan sa active intraocular inflammation.
- Alpha-2 agonists: pagkapagod/pagkahilo, hypotension o heart-rate changes, reduced alertness, ocular irritation/allergic conjunctivitis; contraindicated sa mga batang mas bata sa 2 taon.
- Carbonic anhydrase inhibitors: burning/stinging, mapait na lasa, conjunctival irritation, posibleng metabolic acidosis/electrolyte disturbance risk sa vulnerable clients; posible ang severe sulfonamide hypersensitivity reactions.
- Rho kinase inhibitors: conjunctival hyperemia/hemorrhage, instillation discomfort, increased tearing, corneal verticillata, pansamantalang visual blurring.
Nursing Assessment and Interventions
- Suriin ang baseline ocular status at palakasin ang scheduled IOP follow-up sa ophthalmology.
- Repasuhin ang cardiopulmonary history bago gumamit ng topical beta blocker at i-monitor ang heart rate, blood pressure, breathing status, at fatigue patterns.
- Suriin ang fall risk at orthostatic symptoms, lalo na sa older adults at sa alpha-2 agonist pathways.
- Sa clients na may diabetes, i-monitor ang posibleng pagkatakip ng adrenergic hypoglycemia cues kapag gumagamit ng topical beta blockers.
- Sa renal impairment pathways, i-monitor ang metabolic-acidosis o electrolyte-risk cues habang gumagamit ng carbonic anhydrase inhibitors.
- Palakasin ang punctal (medial canthus) occlusion nang humigit-kumulang 1-2 minuto pagkatapos ng instillation upang mabawasan ang systemic absorption.
- Panatilihin ang ligtas na kapaligiran kapag naaapektuhan ang mobility ng pansamantalang blurred vision o dizziness.
Client Education
- Gamitin ang drops eksakto ayon sa reseta kahit minimal ang sintomas.
- Dumalo sa lahat ng follow-up appointments para sa pressure checks at progression surveillance.
- Alisin ang contact lenses bago mag-administer at maghintay nang humigit-kumulang 15 minuto bago ibalik kapag may ganitong tagubilin.
- I-report agad ang matinding sakit sa mata, pagbaba ng paningin, persistent redness/swelling, dyspnea, wheezing, syncope, o palpitations.
- Iwasan ang pagmamaneho o hazardous activity hanggang sapat na ang visual clarity at alertness pagkatapos ng instillation.
- Kung maraming drops ang reseta, paghiwalayin ang administrations ng humigit-kumulang 5-10 minuto upang mabawasan ang washout.
- Huwag itigil ang therapy nang walang gabay ng prescriber.
Related Concepts
- eye-assessment-visual-acuity-and-common-abnormalities - Tuloy-tuloy na visual-acuity at ocular-change surveillance.
- ophthalmic-medication-administration - Ligtas na instillation technique at contamination prevention.
- beta-blockers - Pagkakatulad ng safety concerns sa systemic at ophthalmic beta blockers.
- alpha-2-agonists - Pagkakatulad sa adrenergic-agonist hemodynamic at CNS monitoring.
- muscarinic-agonists - Karagdagang glaucoma-related miotic pathways.